Ash Alizadeh, MD, PhD (Damon Runyon Clinical Investigator ‘14-‘17) of Stanford University School of Medicine, Stanford, and colleagues reported an analysis of gene expression profiles from ~18,000 human tumors with overall survival outcomes across 39 subtypes of cancer. They developed and applied CIBERSORT, a novel computational approach for associating immune system biomarkers with cancer survival. The researchers hope that these analyses will increase our understanding of cancer biology, aid in the development of new drugs for cancer patients, and enable better prediction of which patients will respond to new and emerging anti-cancer therapies. The study was published in the journal Nature Medicine.
